Enhancing the uptake of dextromethorphan in the CNS of rats by concomitant administration of the P-gp inhibitor verapamil

Life Sciences

Volumn 77, Issue 23, 2005, Pages 2911-2926

  Marier, Jean Francois ^a   Deschênes, Jean Luc ^b   Hage, Amal ^a   Seliniotakis, Eleftheria ^a   Gritsas, Ari ^a   Flarakos, Themis ^a   Beaudry, Francis ^b   Vachon, Pascal ^b  

^a MDS Inc   (Canada)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

CNS; Dextromethorphan; Dextrorphan; P glycoprotein; Verapamil

Indexed keywords

DEXTROMETHORPHAN; GLYCOPROTEIN P INHIBITOR; VERAPAMIL;

ANIMAL EUTHANASIA; ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BLOOD BRAIN BARRIER; CONTROLLED STUDY; DRUG BRAIN LEVEL; DRUG DISPOSITION; DRUG GLUCURONIDATION; DRUG INHIBITION; DRUG PROTEIN BINDING; DRUG STRUCTURE; DRUG UPTAKE; ELECTROSPRAY MASS SPECTROMETRY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; NEUROMODULATION; NONHUMAN; RAT; SPINAL CORD; STRUCTURE ANALYSIS;

ANIMALS; ANTITUSSIVE AGENTS; BRAIN; DEXTROMETHORPHAN; DRUG INTERACTIONS; ENZYME INHIBITORS; MALE; P-GLYCOPROTEIN; RATS; RATS, SPRAGUE-DAWLEY; SPINAL CORD; VERAPAMIL;

EID: 25844499843     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lfs.2005.04.025     Document Type: Article

References (33)

1. D.R. Abernethy, I.W. Wainer, and A.I. Anacleto Verapamil metabolite exposure in older and younger men during steady-state oral verapamil administration Drug Metabolism and Disposition 28 7 2000 760 765
2. C. Advokat, and F.Q. Rhein Potentiation of morphine-induced antinociception in acute spinal rats by the NMDA antagonist dextrorphan Brain Research 699 1 1995 157 160
3. A.J. Bailer Testing for the equality of area under the curves when using destructive measurement techniques Journal of Pharmacokinetics and Biopharmaceutics 16 3 1988 303 309
4. J.L. Bem, and R. Peck Dextromethorphan. An overview of safety issues Drug Safety 7 3 1992 190 199
5. F. Bochner, A.A. Somogyi, and Z.R. Chen Dextromethorphan metabolism in rat: interstrain differences and the fate of individually administered oxidative metabolites Xenobiotica 24 6 1994 543 552
6. K.C. Carlsson, N.O. Hoem, E.R. Moberg, and L.C. Mathisen Analgesic effect of dextromethorphan in neuropathic pain Acta Anaesthesiologica Scandinavica 48 3 2004 328 336
7. 14C]dextromethorphan hydrochloride in rats: levels in plasma and brain Journal of Pharmaceutical Sciences 81 8 1992 750 752
8. T.N. Chase, J.D. Oh, and S. Konitsiotis Antiparkinsonian and antidyskinetic activity of drugs targeting central glutamatergic mechanisms Journal of Neurology 247 Suppl. 2 2000 36 42
9. M. Dematteis, G. Lallement, and M. Mallaret Dextromethorphan and dextrorphan in rats: common antitussives - different behavioural profiles Fundamental and Clinical Pharmacology 12 5 1998 526 537
10. P.H. Elsinga, N.H. Hendrikse, J. Bart, W. Vaalburg, and A. van Waarde PET Studies on P-glycoprotein function in the blood-brain barrier: how it affects uptake and binding of drugs within the CNS Current Pharmaceutical Design 10 13 2004 1493 1503
11. D.J. Hewitt The use of NMDA-receptor antagonists in the treatment of chronic pain Clinical Journal of Pain 16 2 Suppl. 2000 S73 S79
12. K.L. Koszdin, D.D. Shen, and C.M. Bernards Spinal cord bioavailability of methylprednisolone after intravenous and intrathecal administration: the role of P-glycoprotein Anesthesiology 92 1 2000 156 163
13. P. Manitpisitkul, and W.L. Chiou Intravenous verapamil kinetics in rats: marked arteriovenous concentration difference and comparison with humans Biopharmaceutics & Drug Disposition 14 7 1993 555 566
14. C.J. Matheny, M.W. Lamb, K.R. Brouwer, and G.M. Pollack Pharmacokinetic and pharmacodynamic implications of P-glycoprotein modulation Pharmacotherapy 21 7 2001 778 796
15. K.L. Nicholson, B.A. Hayes, and R.L. Balster Evaluation of the reinforcing properties and phencyclidine-like discriminative stimulus effects of dextromethorphan and dextrorphan in rats and rhesus monkeys Psychopharmacology 146 1 1999 49 59
16. L.E. Pope, M.H. Khalil, J.E. Berg, M. Stiles, G.J. Yakatan, and E.M. Sellers Pharmacokinetics of dextromethorphan after single or multiple dosing in combination with quinidine in extensive and poor metabolizers Journal of Clinical Pharmacology 44 10 2004 1132 1142
17. M. Rodriguez, I. Ortega, I. Soengas, E. Suarez, J.C. Lukas, and R. Calvo Effect of P-glycoprotein inhibition on methadone analgesia and brain distribution in the rat Journal of Pharmacy and Pharmacology 56 3 2004 367 374
18. M. Rowland, T.N. Tozer, and R. Rowland Clinical Pharmacokinetics: Concepts and Applications third edition 1995 Lippincott, Williams & Wilkins Media, PA, USA Chapter 3 and 4
19. C.N. Sang NMDA-receptor antagonists in neuropathic pain: experimental methods to clinical trials Journal of Pain and Symptom Management 19 1 Suppl. 2000 S21 S25
20. C.N. Sang, S. Booher, I. Gilron, S. Parada, and M.B. Max Dextromethorphan and memantine in painful diabetic neuropathy and postherpetic neuralgia: efficacy and dose-response trials Anesthesiology 96 5 2002 1053 1061
21. M. Schadel, D. Wu, S.V. Otton, W. Kalow, and E.M. Sellers Pharmacokinetics of dextromethorphan and metabolites in humans: influence of the CYP2D6 phenotype and quinidine inhibition Journal of Clinical Psychopharmacology 15 4 1995 263 269
22. M.K. Shelby, N.J. Cherrington, N.R. Vansell, and C.D. Klaassen Tissue mRNA expression of the rat UDP-glucuronosyltransferase gene family Drug Metabolism and Disposition 31 3 2003 326 333
23. S.H. Sindrup, and T.S. Jensen Efficacy of pharmacological treatments of neuropathic pain: an update and effect related to mechanism of drug action Pain 83 3 1999 389 400
24. G.K. Steinberg, D. Kunis, R. DeLaPaz, and A. Poljak Neuroprotection following focal cerebral ischaemia with the NMDA antagonist dextromethorphan, has a favourable dose response profile Neurological Research 15 3 1993 174 180
25. I. Sugawara, H. Hamada, T. Tsuruo, and S. Mori Specialized localization of P-glycoprotein recognized by MRK 16 monoclonal antibody in endothelial cells of the brain and the spinal cord Japanese Journal of Cancer Research 81 8 1990 727 730
26. J.I. Szekely, L.G. Sharpe, and J.H. Jaffe Induction of phencyclidine-like behavior in rats by dextrorphan but not dextromethorphan Pharmacology, Biochemistry and Behavior 40 2 1991 381 386
27. G. Toffoli, F. Simone, G. Corona, M. Raschack, B. Cappelletto, M. Gigante, and M. Boiocchi Structure-activity relationship of verapamil analogs and reversal of multidrug resistance Biochemical Pharmacology 50 8 1995 1245 1255
28. L. Verhagen Metman, P.J. Blanchet, P. van den Munckhof, P. Del Dotto, R. Natte, and T.N. Chase A trial of dextromethorphan in parkinsonian patients with motor response complications Movement Disorders 13 3 1998 414 417
29. A.A. Weinbroum, B. Bender, J. Bickels, A. Nirkin, N. Marouani, S. Chazam, I. Meller, and Y. Kollender Preoperative and postoperative dextromethorphan provides sustained reduction in postoperative pain and patient-controlled epidural analgesia requirement: a randomized, placebo-controlled, double-blind study in lower-body bone malignancy-operated patients Cancer 97 9 2003 2334 2340
30. D. Wu, S.V. Otton, W. Kalow, and E.M. Sellers Effects of route of administration on dextromethorphan pharmacokinetics and behavioral response in the rat Journal of Pharmacology and Experimental Therapeutics 274 3 1995 1431 1437
31. J.M. Zamora, H.L. Pearce, and W.T. Beck Physical-chemical properties shared by compounds that modulate multidrug resistance in human leukemic cells Molecular Pharmacology 33 4 1988 454 462
32. Y. Zhang, M.R. Britto, K.L. Valderhaug, P.J. Wedlund, and R.A. Smith Dextromethorphan: enhancing its systemic availability by way of low-dose quinidine-mediated inhibition of cytochrome P4502D6 Clinical Pharmacology and Therapeutics 51 6 1992 647 655
33. T. Zysset, T. Zeugin, and A. Kupfer In-vivo and in-vitro dextromethorphan metabolism in SD and DA rat. An animal model of the debrisoquine-type polymorphic oxidation in man Biochemical Pharmacology 37 16 1988 3155 3160